Johnson & Johnson (JNJ)
What's Next For Johnson & Johnson Stock?
Johnson & Johnson (NYSE: JNJ) recently reported its Q3 results, with revenues and earnings exceeding our estimates. The company reported revenue of $22.5 billion and adjusted earnings of $2.42 per share, compared to our estimates of $22.2 billion and $2.20, respectively.
This Magnificent Dividend Stock Is as Healthy as It Gets
Johnson & Johnson's latest financial checkup shows it's still in excellent health.
Johnson & Johnson Stock: Setting the Stage for 2025 Highs
Johnson & Johnson's NYSE: JNJ stock price advance has been reinvigorated. The stock price rally stalled a few years ago due to the COVID-19 bubble bursting and the divestiture of Kenvue NYSE: KVUE, but those days are behind, and business growth is still ahead.
Johnson & Johnson Beats Wall Street Estimates. Is It Time to Buy, Sell, or Hold?
Third-quarter results exceeded estimates, but the company also lowered overall earnings expectations for 2024.
J&J must pay $15 mln to Connecticut man who says its talc gave him cancer, jury finds
Johnson & Johnson must pay $15 million to a Connecticut man who alleges that he developed mesothelioma, a rare form of cancer, as a result of using the company's talc powder for decades, a jury found on Tuesday.
Are JNJ's mergers and acquisitions weighing down company's performance?
Johnson & Johnson (JNJ) stock is experiencing a positive trading day following the announcement of its Q3 results for 2024. The earnings per share (EPS) surpassed estimates, although improved business performance was overshadowed by the recent acquisition of V-Wave, a cardiac device company.
J&J beats Q3 earnings estimates, raises full-year sales guidance
Johnson & Johnson (NYSE:JNJ) shares moved higher after the pharmaceutical giant posted better-than-expected results for the third quarter. Earnings per share (EPS) of $2.42 were down from $2.66 in the year-ago quarter but topped estimates of $2.22.
Johnson & Johnson (JNJ) Q3 2024 Earnings Call Transcript
Johnson & Johnson (NYSE:JNJ ) Q3 2024 Earnings Conference Call October 15, 2024 8:30 AM ET Company Participants Jessica Moore - Vice President, Investor Relations Joaquin Duato - Chairman & Chief Executive Officer Joe Wolk - Executive Vice President, Chief Financial Officer Erik Haas - Head, Worldwide Litigation Tim Schmid - Executive Vice President, Worldwide Chairman, MedTech Jennifer Taubert - Executive Vice President, Worldwide Chairman, Innovative Medicine John Reed - Executive Vice President, Innovative Medicine, R&D Conference Call Participants Chris Schott - JPMorgan Larry Biegelsen - Wells Fargo Louise Chen - Cantor Fitzgerald Terence Flynn - Morgan Stanley Danielle Antalffy - UBS Shagun Singh - RBC Capital Markets Vamil Divan - Guggenheim Securities Jayson Bedford - Raymond James Operator Good morning, and welcome to Johnson & Johnson's Third Quarter 2024 Earnings Conference Call. All participants will be in a listen-only mode until the question-and-answer session of the conference.
J&J Beats on Q3 Earnings, Raises Sales View but Cuts EPS Guidance
JNJ beats estimates for third-quarter earnings and sales. It lowers earnings expectations for 2024 but raises the sales guidance range.
J&J CFO Wolk on Product Pipeline, Strategy and Talc Lawsuit
Johnson & Johnson CFO Joseph Wolk discusses the company's product pipeline, acquisition strategy and the latest on the talc baby powder lawsuit on "Bloomberg Open Interest." J&J reported stronger-than-expected third-quarter earnings, driven by surging sales of cancer medicine Darzalex.
Blue Chip Faces Off With Resistance After Earnings
Shares of Johnson & Johnson (NYSE:JNJ) are up 2.4% to trade at $165.43 this morning, after the company posted a third-quarter beat and hiked its full-year revenue guidance.
Johnson & Johnson Posts Weaker-Than-Expected Profit on Billions in Legal Costs
Johnson & Johnson (JNJ) posted better sales than expected for the third quarter, but profit fell short of analysts' estimates as the company reported billions in one-time expenses like legal costs and acquisitions.
